No Data
Avilen: Amended temporary report
Emerging markets stock digest: AVILEN surged significantly, with Immune Biosciences hitting the limit up.
Stalemate. On the 11th, after the close of trading, the performance for the fiscal year ending August 2024 was announced, and it has been in a stalemate even after starting to rise.
Avilen announced the subsidiary integration of LangCore, an engineering group focused on AI development and rebound.
Rebound. After the trading on the 11th, it was announced that the shares of LangCore, an engineer group specializing in AI-related development, would be acquired and consolidated as a subsidiary, which is viewed as positive news. The acquisition price is 0.4 billion yen. By making LangCore a subsidiary, it is expected to quickly create synergies such as further enhancement of AI technology capabilities, expansion of development projects, and new development of AI SaaS, leading to short-term revenue growth for both companies. It is also expected to result in medium to long-term business expansion.
Shikigaku, the Institute of Immunobiology, and others [Emerging Markets Press Release]
<138A> Hikari Food Service downward revision, this fiscal year operating profit forecast is 20.2 billion yen ← 31.2 billion yen <2981> Launch of a Randyx subsidiary and start of new business <4570> Immune Biology Research Institute acquires patent for "Anti-HIV antibody and its manufacturing method" <4881> Start of collaborative research with Shionogi & Co., Ltd. on Fanpep antibody-induced peptide vaccine adjuvant <5591> Handling entrusted development of AVILEN-generated AI-related systems, etc. by LangCo
Avilen: Extraordinary Report
OpenAI has raised 6.6 billion dollars.
OpenAI has reportedly secured $6.6 billion (approximately 960 billion yen) in its latest funding round. The company's valuation is estimated at $157 billion. It is reported that the company's efforts to build world-class technology in the field of artificial intelligence (AI) will be further strengthened.
No Data
No Data